Abstracts tagged "Vasculitis"

Abstract Number: 2537 • ACR Convergence 2025
Variation in Treatment Approaches in IgA-Vasculitis Among Pediatricians and Pediatric rheumatologists: A Cross-Sectional International Survey
Merav Heshin Bekenstein¹, Tali Elbaz², Yael Illous² and Barak Kandell³, ¹Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ²School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv, Israel, ³The Academic College of Tel Aviv-Yafo, Tel Aviv, Israel
Background/Purpose: IgA Vasculitis (IgAV) is the most common small-vessel vasculitis in children. Although there is no evidence-based recommendations for treating IgAV, the European SHARE recommendations…
Abstract Number: 1767 • ACR Convergence 2025
Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis
Claire Galand¹, Fei Liu², Katherine Vernon², Ravi Vats², Christine Lian³, V. Michael Holers⁴, H. Terence Cook⁵, David Cuthbertson⁶, Nader Khalidi⁷, Curry Koening⁸, Carol Langford⁹, Carol McAlear¹⁰, Paul Monach¹¹, Christian Pagnoux¹², Jason Campagna², Shelia Violette² and Peter Merkel¹⁰, ¹Q³² Bio Inc,, Waltham, MA, ²Q³² Bio Inc, Waltham, MA, ³Department of Pathology, Brigham & Women’s Hospital/Harvard Medical School, Boston, MA, ⁴University of Colorado Anschutz Medical Campus, Aurora, ⁵Department of Immunology and Inflammation, Imperial College London, London, United Kingdom, ⁶University of South Florida, Tampa, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Texas Dell Medical School, Austin, TX, ⁹Cleveland Clinic, Moreland Hills, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹VA Boston Healthcare System, Boston, MA, ¹²Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: One proposed mechanism of tissue damage in ANCA-associated vasculitis (AAV) is the formation of neutrophil extracellular traps (NETs) during extravasation of neutrophils into and…
Abstract Number: 1607 • ACR Convergence 2025
Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort
Natasha Le Blanc¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Nataliya Milman⁹, Medha Soowamber¹⁰, Nader Khalidi¹¹, Christian Pagnoux¹⁰, Rosalie-Selene Meunier¹², Jan Willem Cohen Tervaert⁴, Elaine Yacyshyn⁴ and Arielle Mendel¹³, ¹McGill University, Montreal, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Self employed, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Universite de Montreal, Montreal, Canada, ⁹the Ottawa Hospital, Ottawa, ON, Canada, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Hopital du Sacre-Coeur-de-Montreal, Montreal, QC, Canada, ¹³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Antibiotic prophylaxis is recommended during initial treatment of ANCA-associated vasculitis (AAV). We assessed characteristics associated with prophylaxis within a Canadian multicenter AAV cohort starting…
Abstract Number: 0715 • ACR Convergence 2025
Supervised machine learning algorithm to identify patients with eosinophilic granulomatosis with polyangiitis in France
Benjamin Terrier¹, Solenne Tauty², Anouar Salhi², Francoise Bugnard², Steve Benard², Vincent Cottin³, Camille Taillé⁴ and Xavier Puéchal⁵, ¹Cochin Hospital, Paris, France, ²Steve Consultants, Lyon, France, ³National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon ¹, UMR ⁷⁵⁴, ERN-LUNG, Lyon, France, Lyon, France, ⁴Bichat hospital, APHP, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France
Background/Purpose: Identifying patients with eosinophilic granulomatosis with polyangiitis (EGPA) in claims databases such as the French National Health Data System (SNDS) is a major challenge…
Abstract Number: 0744 • ACR Convergence 2025
Age and Sex Influence on Clinical Manifestations of Giant Cell Arteritis: Results from the ARTESER Registry
Delia Fernandez-Lozano¹, Marta Domínguez-Álvaro², Javier Narváez³, Noemí Garrido⁴, Eugenio de Miguel⁵, Paula Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maite Silva-Diaz⁸, Joaquín M Belzunegui⁹, Clara Moriano¹⁰, Julio Sánchez Martín¹¹, Itziar Calvo-Zorrilla¹², Vicente Aldasoro Cáceres¹³, lydia Abasolo Alcazar¹⁴, Javier Loricera¹⁵, rafeal Benito-Melero¹⁶, Maria Garcia-Villanueva¹⁷, Fernando Sánchez-Alonso², Santos Castañeda¹⁸, José L. Hernández¹⁹ and Ricardo Blanco²⁰, ¹Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ⁹Hospital Universitario Donostia, San Sebastian, Spain, ¹⁰Hospital León, LEON, Castilla y Leon, Spain, ¹¹Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹²Galdakao-Usansolo University Hospital, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴IdISSC. HCSC, Madrid, Madrid, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹⁶MD, barcelona, Spain, ¹⁷Hospital Ramón y Cajal, Madrid, Spain, ¹⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁹Instituto de Investigación Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis that predominantly affects older adults, with a higher prevalence in women. Previous studies exploring sex-related…
Abstract Number: 0029 • ACR Convergence 2025
A Novel B Cell Subpopulation Characteristic of IgA Vasculitis Identified by Single-Cell RNA Sequencing
Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil², Evan Troendle³, Oisin Cappa³, Maite Leonardo⁴, Ana Peñalba⁴, Luis mARTIN pENAGOS⁵, Ligia Gabrie-Rodriguez⁶, Rafael Gálvez Sánchez⁶, Jose Luis Callejas⁷, Belen Sevilla⁸, Diego de Argila⁹, Esther Vicente-Rabaneda⁹, Santos Castañeda¹⁰, David Simpson³, Ricardo Blanco¹¹, Verónica Pulito Cueto¹ and Raquel Lopez Mejias¹, ¹IDIVAL, Santander, Spain, ²Immunopathology Group, IDIVAL, Santander, Spain, ³Queens University, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, United Kingdom, ⁴Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Immunopathology Group, IDIVAL and Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁷Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ⁸Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁹Hospital Universitario de la Princesa, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgA vasculitis (IgAV) is a systemic small-vessel vasculitis characterized by immune complex deposition containing aberrantly glycosylated IgA1. While its clinical manifestations are well defined…
Abstract Number: 2532 • ACR Convergence 2025
Temporal arteritis revealing eosinophilic diseases: A multicenter retrospective study, literature review, and combined cluster analysis
Julie Merindol¹, Benjamin Torreau², Matthieu Groh³, Amy Klion⁴, Paolo Delvino⁵, Olivier Espitia⁶, Jean-Benoit Arlet⁷, Sarah Lechtman⁸, Jean-sébastien Allain⁹, Federica Bello¹⁰, Anaelle Boucaud¹¹, Florian Catros¹², Julien Campagne¹³, Anne Coutard¹⁴, Cecile-Audrey DUREL¹⁵, Mikael Ebbo¹⁶, Georgina Espigol-Frigole¹⁷, Giacomo Emmi¹⁸, Yanis Kouchit¹⁹, Guillaume Lefevre²⁰, François Lifermann²¹, PAUL LEGENDRE²², Eric Liozon²³, Francois Maurier²⁴, Sara Melboucy Belhkir²⁵, Sébastien Miranda²⁶, Simon Parreau²³, Paola Parronchi²⁷, Jacques Pouchot²⁸, Vincent Pestre²⁹, Sophie Rosenstingl³⁰, Jan Willem Cohen Tervaert³¹, Odile Souchaud Debouverie³², Xavier Puéchal³³ and Benjamin Terrier³⁴, ¹CHU de Nice, Nice, France, ²Internal Medicine and Immunology, CHU Tours, Tours, France, ³Hôpital Foch, paris, France, ⁴NIAID/NIH, Bethesda, MD, ⁵University of Milano-Bicocca, Monza, Monza and Brianza, Italy, ⁶CHU de Nantes, Nantes, France, ⁷APHP, Paris, ⁸CHU de Nice, Nixe, France, ⁹Scorff-Lorient Hospital, Lorient, France, ¹⁰Université de Florence, Florence, Italy, ¹¹CHU de Tours, Tours, France, ¹²CHI VAL, Ariège, France, ¹³Hopital Robert Schuman, Metz, France, ¹⁴Groupe Hospitalier de Bretagne Sud, Lorient, France, ¹⁵CHU de Lyon, Lyon, France, ¹⁶Internal Medicine, Marseille-APHM, hôpital La Timone, Marseille, France, ¹⁷Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁸Department of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, Trieste, Italy, ¹⁹CH de Cannes, Cannes, France, ²⁰CHU de Lille, Lille, France, ²¹Internal Medicine, CH de Dax, Dax, France, ²²CH LE MANS, Le Mans, France, ²³CHU de Limoges, Limoges, France, ²⁴HOPITAUX PRIVES DE METZ, Vaux / Frankreich, France, ²⁵CH de Saint Quentin, Saint Quentin, France, ²⁶Internal Medicine, CHU Rouen, Rouen, France, ²⁷CHU de Florence, Florence, Italy, ²⁸AP-HP, Rueil Malmaison, France, ²⁹CH d'Avignon, Avignon, France, ³⁰CH de Compiegne, Compiegne, France, ³¹University of Alberta, Edmonton, AB, Canada, ³²CHU de Poitiers, Poitiers, France, ³³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ³⁴Cochin Hospital, Paris, France
Background/Purpose: Temporal arteritis (TA) classically presents as a large-vessel vasculitis in older adults with cranial ischemic symptoms. However, in younger patients or in the presence…
Abstract Number: 1765 • ACR Convergence 2025
Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial
Xavier Puéchal¹, Grégory Pugnet², Elisabeth Diot³, Claire de Moreuil⁴, Stéphane Jouneau⁵, Thomas Quemeneur⁶, Gabriel Baron⁷, Perrine Smets⁸, Antoine Néel⁹, Thomas Le Gallou¹⁰, Nicolas Noël¹¹, Yurdagül Uzunhan¹², Cloé Comarmond¹³, Geoffrey Urbanski¹⁴, Ygal Benhamou¹⁵, Alice Bérezné¹⁶, Arsène Mekinian¹⁷, Mohamed Hamidou⁹, Julien Campagne¹⁸, Noemie Abisror¹⁹, Benjamin Torreau³, Pascal Cohen²⁰, Loic Guillevin²⁰, Philippe Ravaud⁷ and Benjamin Terrier²¹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³Internal Medicine and Immunology, CHU Tours, Tours, France, ⁴CHU DE BREST, BREST, France, ⁵Respiratory Medicine, Université de Rennes ¹, CHU Pontchaillou, Rennes, France, ⁶Nephrology and Internal Medicine, CH Valenciennes, Valenciennes, France, ⁷Hôtel-Dieu, Université Paris Cité,, Paris, France, ⁸Internal Medicine, CHU Gabriel-Montpied, Clermont-Ferrand, France, ⁹Internal Medicine, CHU Hôtel-Dieu, Nantes, France, ¹⁰Internal Medicine and Clinical Immunology, CHU Rennes Sud, Rennes, ¹¹Internal Medicine and Clinical Immunology, CHU Bicêtre, Bicêtre, ¹²Respiratory Medicine, Hôpital Avicenne, Bobigny, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ¹⁴Internal Medicine and Clinical Immunology, CHU Angers, Angers, France, ¹⁵Internal Medicine, CHU Rouen, Rouen, France, ¹⁶Internal Medicine, CH, Annecy, Annecy, France, ¹⁷Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁸Internal Medicine, CH Robert Schuman, Metz, France, ¹⁹Internal Medicine, CHU Saint-Antoine,, Paris, France, ²⁰Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²¹Cochin Hospital, Paris, France
Background/Purpose: The eosinophilic granulomatosis with polyangiitis (EGPA) guidelines recommend considering maintenance therapy after remission to reduce the risk of relapse and toxicity, but data on…
Abstract Number: 1605 • ACR Convergence 2025
Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Miriam Guerini¹, Pavel Novikov², Roberto Padoan³, Georgina Espigol-Frigole⁴, Jan Willem Cohen Tervaert⁵, Vincent Grobost⁶, Laurent Guilleminault⁷, Jan Walter Schroeder⁸, Bernhard Hellmich⁹, Joana Martins-Martinho¹⁰, Camillo Ribi¹¹, Mathieu Groh¹² and Benjamin Terrier¹³, ¹IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ²Sechenov University, Moscow, Russia, ³University of Padova, Padova, Italy, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Internal medicine, CHU Clermont Ferrand Estaing, Clermont Ferrand, France, ⁷CHU Toulouse, Toulouse University, Toulouse, France, ⁸ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁹Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim, Kirchheim unter Teck, Germany, ¹⁰ULS Santa Maria, Lisbon, Portugal, ¹¹Lausanne University Hospital / University of Lausanne, Lausanne, Switzerland, ¹²Hôpital Foch, Suresnes, France, ¹³Cochin Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, ear, nose, and throat (ENT) symptoms, eosinophilia, and systemic involvement. Despite the…
Abstract Number: 0714 • ACR Convergence 2025
Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort
Alvaro Oyarce-Calderón¹, Allison Figueroa-Sánchez², Leonor León-Yaurimucha², Rocío Gamboa-Cárdenas³, Zoila Rodríguez-Bellido⁴, Risto Perich-Campos⁵, Graciela Alarcón⁶, Manuel Ugarte-Gil⁷ and Victor Pimentel-Quiroz⁸, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁶The University of Alabama at Birmingham, Oakland, CA, ⁷Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁸Universidad Científica del Sur, San Isidro, Peru
Background/Purpose: Depression and anxiety symptoms have been reported in 28% of patients suffering from vasculitides. However, in patients with ANCA-associated vasculitis (AAV), their frequency and…
Abstract Number: 0743 • ACR Convergence 2025
Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
David O'Dea¹, Guy Katz¹, Belen Arevalo Molina¹, Adam Jarvie², Mark Matza¹, Ana Fernandes¹, John Stone³ and Sebastian H Unizony⁴, ¹Massachusetts General Hospital, Boston, MA, ²Emory University School of Medicine, Atlanta, GA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The optimal duration of tocilizumab (TCZ) treatment for giant cell arteritis (GCA) is unclear. Observational studies have shown that 50-60% of patients relapse after…
Abstract Number: 0025 • ACR Convergence 2025
Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
Elio Carmona¹, Rabia Deniz², Cemal Bes³, Haner Direskeneli⁴, Ahmet Gul⁵ and Amr Sawalha⁶, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ³University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ⁴Marmara University, ISTANBUL, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Behçet’s disease (BD) is a chronic, relapsing inflammatory disease characterized by complex immunopathogenesis and limited treatment options. Monocytes are known to play a significant…
Abstract Number: 2525 • ACR Convergence 2025
Point-of-Care Risk Factors for Systemic Disease in Patients Presenting with Small Vessel Vasculitis of the Skin
Arjun Mahajan¹, William Song², Andrew Walls³, Arash Mostaghimi³, Robert Micheletti² and Evan Piette³, ¹Harvard Medical School, Boston, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Brigham and Women's Hospital, Harvard Medical School, Boston
Background/Purpose: Small vessel vasculitis (SVV) presenting in the skin may be skin-limited or a manifestation of systemic vasculitis or an underlying autoimmune disease. However, no…
Abstract Number: 1764 • ACR Convergence 2025
Development and Validation of a Simulation Model for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Naomi Patel¹, Aaron Wu², Eli Miloslavsky³, Peter Merkel⁴, John Stone⁵, Hyon K. Choi⁶, Zachary Wallace³ and Emily Hyle², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Evaluating the effectiveness and safety profile of treatment strategies for the induction of remission of individuals with newly diagnosed AAV is important for guiding…
Abstract Number: 1604 • ACR Convergence 2025
Impact and risk factors of anti-rituximab antibodies in small-vessel vasculitis: a multicenter retrospective study
Lucas Khellaf¹, Raphaele Seror², caterina ricordi³, stephanie chhun⁴, audes gleizes⁴, hervé lobbes⁵, clara pouchelon⁶, marie Charlotte Besse⁷, Jean-Emmanuel Kahn⁸, sabine revuz⁹, Marina Cumin¹⁰, Dimitri Titeca-Beauport¹¹, Matthias Papo⁶, Philippe Rémy⁶, marie Desprets¹², florian garo¹³, Charles Ronsin¹⁴, Salima Hacein-Bey-Abina⁶, Amélie Servettaz¹⁵, Cacoub Patrice¹⁶, Xavier Puéchal¹⁷ and Benjamin Terrier¹⁸, ¹AP-HP, Paris, ²Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ³Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ⁴APHP, Paris, Ile-de-France, France, ⁵Department of Internal Medicine, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, ⁶APHP, Paris, France, ⁷CHU Tours, Tours, France, ⁸Ambroise Paré hospital, Boulogne, France, ⁹CHU de la Réunion, Réunion, France, ¹⁰Centre hospitalier de Libourne, Libourne, France, ¹¹CHU Amiens, Amiens, France, ¹²CH Chôlet, Cholet, France, ¹³CHU Nîmes, Nîmes, France, ¹⁴CHU Nantes, Nantes, France, ¹⁵Internal Medicine, CHU Reims, Reims, France, ¹⁶Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹⁸Cochin Hospital, Paris, France
Background/Purpose: Small vessel vasculitis mainly includes ANCA-associated vasculitis (AAV) and cryoglobulinemic vasculitis (CV), leading to significant organ damage. Rituximab (RTX), an anti-CD20 monoclonal antibody, has…

« Previous Page
1
…
4
5
6
7
8
…
41
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].